GW3965 |
| Catalog No.GC16964 |
An orally-active agonist of LXRα and LXRβ
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 405911-09-3
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
GW3965 is a potent and selective activitor of liver X receptors (LXRs) with EC50 value of 190 and 30 nM respectively to hLXRαand hLXRβ.[1]
Liver X receptors belong to the nuclear receptor family. They are classified into subfamily 1 of the nuclear receptor superfamily. There are two isforms of LXRs and they are LXRαand LXRβ. LXRs play an important role in regulating glucose, fatty acid, and cholesterol homeostasis. Crystal analysis show that human LXRβ (liver X receptor β) forms heterodimer with retinoid X receptor α(RXRα) which is the partner on its cognate element. Before activation, LXRα and LXRβ can form heterodimers with the partner 9-cis RXR (retinoic acid receptor). The heterodimer will be activated by an LXR agonist or a RXR agonist. After activation, LXR will binds to LXR response element and regulated related gene expression.[2]
GW3965 can result in promotion of tumor cell death and inhibition of cell growth in GBM cells at 2μM. GW3965 treatment at 2μM can significantly promote increases in mRNA levels of ABCA1 and IDOL, then induced cell death.[3]
GW3965 significantly reduced LDLR expression and induced ABCA1 expression in mice which was implanted U87/EGFRvIII cells at 40 mg/kg. GW3965 also blocked tumor growth at this dose.[3] GW3965 increased the expression of ABCA1and apoE at 30 mg/kg/d in APP/PS1 mice.[4]
References:
[1]. Zhang Y, Ge C, Wang L, Liu X, Chen Y, Li M, Zhang M: Induction of DKK1 by ox-LDL negatively regulates intracellular lipid accumulation in macrophages. FEBS Lett, 589(1):52-58.
[2]. Spyridon M, Moraes LA, Jones CI, Sage T, Sasikumar P, Bucci G, Gibbins JM: LXR as a novel antithrombotic target. Blood, 117(21):5751-5761.
[3]. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S et al: An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov, 1(5):442-456.
[4]. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL: ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem, 285(44):34144-34154.
| Cell experiment [1,2]: | |
|
Cell lines |
U87 and U87-EGFRvIII GBM cells, |
|
Preparation method |
Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
2-5 μM, 4 days |
|
Applications |
In U87 and U87-EGFRvIII GBM cells, treatment with GW3965 (2-5 μM) for 4 days dose-dependently inhibited growth and promoted tumor cell death. Low-dose GW3965 (1 or 2 μM) induced ABCA1. In U87 and U87-EGFRvIII GBM cells, GW3965 (5 μM, 24h) upregulated expression of the cholesterol transporter gene ABCA1 and the E3 ubiquitin ligase IDOL and reduced LDLR levels. GW3965 (1 or 5 μM) displayed a minor inhibitory effect on fibrinogen binding and P-selectin exposure. GW3965 (10 μM) reduced the levels of fibrinogen and P-selectin on the platelet surface. |
| Animal experiment [1,2]: | |
|
Animal models |
SCID/Beige mice xenografted with isogenic human malignant glioma cells (U87, U87-EGFRvIII); C57BL/6 mice |
|
Dosage form |
Oral gavage, 40 mg/kg, daily for 12 days |
|
Application |
In mice bearing U87/EGFRvIII cells, GW3965 (40 mg/kg daily by oral gavage) for 12 days potently inhibited GBM growth, promoted tumor cell death and inhibited tumor growth. In C57BL/6 mice, GW3965 (2 mg/kg, i.v.) increased bleeding time and modulated platelet thrombus formation. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Guo D, Reinitz F, Youssef M, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR–dependent pathway[J]. Cancer discovery, 2011. [2]. Spyridon M, Moraes L A, Jones C I, et al. LXR as a novel antithrombotic target[J]. Blood, 2011, 117(21): 5751-5761. | |
| Cas No. | 405911-09-3 | SDF | |
| Chemical Name | 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid | ||
| Canonical SMILES | C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4 | ||
| Formula | C33H31ClF3NO3 | M.Wt | 582.05 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7181 mL | 8.5903 mL | 17.1807 mL |
| 5 mM | 0.3436 mL | 1.7181 mL | 3.4361 mL |
| 10 mM | 0.1718 mL | 0.859 mL | 1.7181 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *